Burin Sandra Mara, Ghisla Sandro, Ouchida Amanda Tomie, Aissa Alexandre Ferro, Coelho Maria Gabriela Berzoti, Costa Tássia Rafaella, Marsola Ana Paula Zambuzi Cardoso, Pinto-Simões Belinda, Antunes Lusânia Maria Greggi, Curti Carlos, Sampaio Suely Vilela, de Castro Fabíola Attié
Department of Clinical Analysis, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo-USP, Ribeirão Preto, SP, Brazil.
Department of Biology, University of Konstanz, Konstanz, Germany.
Int J Biol Macromol. 2016 May;86:309-20. doi: 10.1016/j.ijbiomac.2016.01.069. Epub 2016 Jan 23.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Bcr-Abl tyrosine kinase protein, which confers resistance to apoptosis in leukemic cells. Tyrosine kinase inhibitors (TKIs) are effectively used to treat CML; however, CML patients in the advanced (CML-AP) and chronic (CML-CP) phases of the disease are usually resistant to TKI therapy. Thus, it is necessary to seek for novel agents to treat CML, such as the enzyme l-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) snake venom. We examined the antitumor effect of CR-LAAO in Bcr-Abl(+) cell lines and peripheral blood mononuclear cells (PBMC) from healthy subjects and CML patients. CR-LAAO was more cytotoxic towards Bcr-Abl(+) cell lines than towards healthy subjects' PBMC. The H2O2 produced during the enzymatic action of CR-LAAO mediated its cytotoxic effect. The CR-LAAO induced apoptosis in Bcr-Abl(+) cells, as detected by caspases 3, 8, and 9 activation, loss of mitochondrial membrane potential, and DNA damage. CR-LAAO elicited apoptosis in PBMC from CML-CP patients without TKI treatment more strongly than in PBMC from healthy subjects and TKI-treated CML-CP and CML-AP patients. The antitumor effect of CR-LAAO against Bcr-Abl(+) cells makes this toxin a promising candidate to CML therapy.
慢性髓系白血病(CML)是一种骨髓增殖性肿瘤,其特征是存在Bcr-Abl酪氨酸激酶蛋白,该蛋白赋予白血病细胞抗凋亡能力。酪氨酸激酶抑制剂(TKIs)可有效用于治疗CML;然而,处于疾病进展期(CML-AP)和慢性期(CML-CP)的CML患者通常对TKI治疗耐药。因此,有必要寻找治疗CML的新型药物,如来自红口蝮蛇(CR-LAAO)蛇毒的L-氨基酸氧化酶。我们检测了CR-LAAO对Bcr-Abl(+)细胞系以及健康受试者和CML患者外周血单个核细胞(PBMC)的抗肿瘤作用。与健康受试者的PBMC相比,CR-LAAO对Bcr-Abl(+)细胞系的细胞毒性更大。CR-LAAO酶促作用过程中产生的H2O2介导了其细胞毒性作用。通过检测半胱天冬酶3、8和9的激活、线粒体膜电位丧失和DNA损伤发现,CR-LAAO可诱导Bcr-Abl(+)细胞凋亡。与健康受试者以及接受TKI治疗的CML-CP和CML-AP患者的PBMC相比,CR-LAAO对未经TKI治疗的CML-CP患者的PBMC诱导凋亡的作用更强。CR-LAAO对Bcr-Abl(+)细胞的抗肿瘤作用使其成为CML治疗的一个有前景的候选药物。